The company has ditched a trial of drebuxelimab plus ivonescimab.
ApexOnco Front Page
Recent articles
CRB-601 and PF-06940434 fall by the wayside.
The group has canned its first-generation project, hoping that a follow-on will reach more patients.
LaNova, which licensed a PD-1 x VEGF to Merck, is acquired by another Chinese player.
The company will start a phase 2/3 trial of its Mirati-originated PRMT5 inhibitor in autumn.
The disappointing Pynnacle trial is set to yield registrational data.
A single but durable stable disease sends the microcap's stock up 730%.
MK-8294 starts phase 1, but its mechanism is anybody's guess.
